Donald Ganem, Via Nova Therapeutics. “The Looming Crisis in Antibiotic Development”
Donald Ganem is a virologist and microbiologist who has made significant contributions to the understanding of viral infections as well as the development of new infectious disease treatments. Ganem is a microbiology and immunology professor at the University of California, San Francisco, and the global head of infectious disease research at Novartis Institutes for BioMedical Research.
Ganem has made numerous groundbreaking discoveries in the field of virology throughout his career, including the identification of Kaposi’s sarcoma-associated herpesvirus (KSHV), a virus linked to several types of cancer. His research has also led to the identification of new targets for antiviral therapies, such as hepatitis B virus inhibitors.
At Via Nova Therapeutics, Ganem has applied his expertise in virology to guide the development of new antiviral therapies. As founder and CEO, he has been instrumental in his company’s identification of novel targets for drug development, evaluation of potential drug candidates, and provision of strategic guidance to the company’s leadership team. Ganem’s extensive research on viral infections has earned him numerous awards and honors, including the Robert Koch Prize and the Lasker-DeBakey Clinical Medical Research Award.